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Berberine Ameliorates Hepatic 
Steatosis and Suppresses Liver and 
Adipose Tissue Inflammation in 
Mice with Diet-induced Obesity
Ting Guo1,*, Shih-Lung Woo1,*, Xin Guo1, Honggui Li1, Juan Zheng1,2, Rachel Botchlett1, 
Mengyang Liu1, Ya Pei1, Hang Xu1, Yuli Cai1,2, Tianshu Zeng2, Lulu Chen2, Xiaodong Li3, 
Qifu Li4, Xiaoqiu Xiao4,5, Yuqing Huo6,7 & Chaodong Wu1
Increasing evidence demonstrates that berberine (BBR) is beneficial for obesity-associated non-
alcoholic fatty liver disease (NAFLD). However, it remains to be elucidated how BBR improves aspects 
of NAFLD. Here we revealed an AMP-activated protein kinase (AMPK)-independent mechanism for BBR 
to suppress obesity-associated inflammation and improve hepatic steatosis. In C57BL/6J mice fed a 
high-fat diet (HFD), treatment with BBR decreased inflammation in both the liver and adipose tissue as 
indicated by reduction of the phosphorylation state of JNK1 and the mRNA levels of proinflammatory 
cytokines. BBR treatment also decreased hepatic steatosis, as well as the expression of acetyl-CoA 
carboxylase and fatty acid synthase. Interestingly, treatment with BBR did not significantly alter the 
phosphorylation state of AMPK in both the liver and adipose tissue of HFD-fed mice. Consistently, BBR 
treatment significantly decreased the phosphorylation state of JNK1 in both hepatoma H4IIE cells 
and mouse primary hepatocytes in both dose-dependent and time-dependent manners, which was 
independent of AMPK phosphorylation. BBR treatment also caused a decrease in palmitate-induced 
fat deposition in primary mouse hepatocytes. Taken together, these results suggest that BBR actions 
on improving aspects of NAFLD are largely attributable to BBR suppression of inflammation, which is 
independent of AMPK.
Non-alcoholic fatty liver disease (NAFLD) encompasses the whole spectrum of liver diseases including hepatic 
steatosis, non-alcoholic steatohepatitis (NASH), and cirrhosis that are not associated with significant alcohol 
consumption1. While simple steatosis is largely considered benign, NAFLD could progress to its advanced stage, 
NASH, if the liver displays overt necroinflammation, and could eventually progress to cirrhosis, liver failure 
and liver cancer2–4. Many epidemiological studies have demonstrated that the incidence of NAFLD is markedly 
increased in obese populations1,5,6. Consistently, in rodent models of diet-induced obesity (DIO), hepatic steatosis 
and inflammation are characteristics that are commonly associated with systemic insulin resistance and glucose 
metabolic dysregulation. Indeed, hepatic steatosis is sufficient to trigger inflammatory responses7,8 and to induce 
liver insulin resistance by activating protein kinase Cε 9. Furthermore, hepatic steatosis is a major contributor of 
dyslipidemia that works with or without insulin resistance to significantly increase the incidence of atherogenic 
cardiovascular diseases10. Because of this, NAFLD is considered a critical component of metabolic syndrome.
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The exact mechanisms underlying the pathogenesis of NAFLD remain to be explored. Because of the close 
relationship between obesity and NAFLD, obesity-associated inflammation and insulin resistance are accepted as 
key factors that initiate or exacerbate NAFLD. For instance, both inflammation and insulin resistance can cause 
hepatic steatosis through increasing liver expression of genes for lipogenic enzymes such as acetyl-CoA carbox-
ylase 1 (ACC1) and fatty acid synthase (FAS) and decreasing liver expression of genes for fatty acid oxidation 
including carnitine palmitoyltransferase 1a (CPT1a)11–13. In terms of generating inflammatory mediators, adipose 
tissue has been implicated as an essential location where a number of proinflammatory cytokines are released 
and, in turn, bring about the secondary effects on the liver to serve as a “second hit” to exacerbate NAFLD during 
obesity14. Interestingly, adipose tissue also releases palmitoleate, which, at increased levels, stimulates hepatic 
steatosis, but suppresses liver inflammatory responses15,16. Clearly, the inflammatory status, at both the liver and 
systemic levels, is of particular importance to the development and progression of NAFLD, and this inflammation 
can occur independent of fat deposition15,16.
Berberine (BBR), a natural compound found in numerous herb plants including Coptis Chinensis, has received 
much attention as many animal studies and clinical trials have reported anti-hyperglycemia and anti-dyslipidemia 
effects of BBR17–20. Of interest, BBR also displays a potent effect on reducing hepatic steatosis as supported by the 
results from both animal and clinical investigations19–21. This anti-hepatic steatosis effect of BBR is attributable 
to, at least in part, the actions of BBR on reducing the methylation of the microsomal triglyceride transfer pro-
tein (MTTP) promoter19 and on decreasing the DNA demethylation and histone acetylation in regulation of 
L-pyruvate kinase22. Because of the essential role played by AMP-activated protein kinase (AMPK) in fat metab-
olism23, a number of studies have also demonstrated AMPK as a critical mediator responsible for the anti-hepatic 
steatosis effect of BBR21. However, the extent to which the anti-inflammatory effect of BBR contributes to its 
anti-NAFLD effect remains largely unknown; although BBR is well recognized as a classic anti-inflammatory 
natural compound and is shown to inhibit hepatocyte inflammatory responses24. Considering the importance of 
inflammation in the development and progression of NAFLD, the present study examined the anti-inflammatory 
effect of BBR in the context of improving NAFLD. Our novel findings suggested an AMPK-independent mecha-
nism for BBR actions on improving obesity-associated hepatic steatosis and inflammation.
Results
Berberine ameliorates obesity-associated systemic insulin resistance and glucose intoler-
ance. Upon feeding of a high-fat diet (HFD) for 4 weeks, C57BL/6J mice started to demonstrate a significant 
increase in body weight (diet-induced obesity, DIO) compared with age- and gender-matched mice on a low-fat 
diet (LFD) (Fig. 1A). At the end of 12 week feeding/treatment period, HFD-fed and phosphate-buffered saline 
(PBS)-treated (HFD-PBS) mice gained much more body weight than LFD-fed and PBS-treated (LFD-PBS) mice 
(P < 0.001, HFD-PBS vs. LFD-PBS). Within HFD-fed mice, treatment with BBR did not alter body weight and 
food intake compared with HFD-PBS control mice (Fig. 1A,B). However, HFD-fed and BBR-treated (HFD-BBR) 
mice displayed a significant decrease in the severity of obesity-associated systemic insulin resistance and glucose 
intolerance (Fig. 1C,D) compared with HFD-PBS mice. These results suggest that BBR improves systemic insulin 
sensitivity and glucose homeostasis in the absence of altering body weight.
Berberine decreases obesity-associated liver inflammation. Since inflammation is a critical factor 
that drives the progression of simple steatosis to NASH4,5, we examined the inflammatory signaling through JNK 
and quantified the mRNA levels of proinflammatory cytokines to assess BBR action on the liver inflammatory sta-
tus. Compared with that in livers of LFD-PBS mice, the phosphorylation state of JNK1 (p46) in livers of HFD-PBS 
mice showed a 5.5-fold increase (Fig. 2A,B). Upon treatment with BBR, the phosphorylation state of liver p46 
was significantly decreased compared with that of HFD-PBS mice (56% decrease; Fig. 2A,B). Next, we examined 
the mRNA levels of proinflammatory cytokines including IL-1β , IL-6, and TNFα , which all were significantly 
increased in livers of HFD-PBS mice when compared with their respective levels in livers of LFD-PBS mice. 
Upon treatment with BBR, liver mRNA levels of IL-1β and TNFα were significantly decreased while liver mRNA 
levels of IL-6 were not significantly altered (Fig. 2C). These results suggest that treatment with BBR ameliorates 
obesity-associated liver inflammation.
Berberine ameliorates obesity-associated hepatic steatosis without altering AMPK phospho-
rylation. Hepatic steatosis is a characteristic of NAFLD, whose incidence is markedly increased by obesity. 
We measured liver weight and did not observe significant differences between HFD-BBR mice and HFD-PBS 
mice (Fig. 3A); although liver weight of HFD-BBR mice or HFD-PBS mice was significantly greater than that of 
LFD-PBS mice. Compared with LFD-PBS mice, HFD-PBS mice displayed a marked increase in liver fat deposi-
tion, validating obesity-associated hepatic steatosis (Fig. 3B). However, the severity of obesity-associated hepatic 
steatosis was significantly decreased in HFD-BBR mice compared with that in HFD-PBS mice as indicated by 
results of H&E staining and Oil Red O staining. Since AMPK plays a critical role in the pathogenesis of hepatic 
steatosis23,25,26, we examined AMPK signaling. Compared with that in LFD-PBS mice, the phosphorylation state 
of liver AMPK in HFD-PBS mice was significantly decreased. This decrease, however, was not recovered by treat-
ment with BBR (Fig. 3C); although BBR brought about a significant decrease in the severity of obesity-associated 
hepatic steatosis. Similar trends were also observed for the phosphorylation state of ACC. In contrast, treat-
ment with BBR brought about a significant decrease in the mRNA levels of genes related to lipogenesis such as 
ACC, FAS, and sterol regulatory element-binding protein 1c (SREBP1c) although BBR decreased the mRNA 
levels of CPT1a, a rate-determining enzyme that favors fatty acid oxidation (Fig. 3D). These results suggest that 
BBR amelioration of obesity-associated hepatic steatosis involves in a decrease in liver lipogenesis, which is 
AMPK-independent.
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Berberine improves hepatocyte inflammatory and metabolic responses. To examine the 
direct effects of BBR on hepatocyte inflammatory and metabolic responses, we performed dose-response and 
time-course studies using H4IIE cells, a rat hepatoma cell line26. In the time-course study, H4IIE cells were treated 
with BBR at a dose of 25 μM for various time periods. Under basal (bovine serum albumin (BSA)-treated) condi-
tions, BBR treatment significantly decreased the phosphorylation state of p46 at a time point as early as 10 min. 
Furthermore, the effect of BBR on decreasing the phosphorylation state of p46 displayed a time-dependent 
manner between 1 hr- and 8 hr-post BBR treatment (Fig. 4A). Under palmitate-stimulated conditions where the 
phosphorylation state of p46 was increased, treatment with BBR was still able to decrease palmitate-stimulated 
p46 phosphorylation, but required a relatively longer time period, i.e., at least 4 hr (Fig. 4A). Consistently, the 
effect of BBR on decreasing the phosphorylation state of p46 also revealed a time-dependent manner between 
1 hr- and 8 hr-post BBR treatment under palmitate-stimulated conditions. In contrast, under both basal and 
palmitate-stimulated conditions, the phosphorylation state of hepatocyte AMPK did not differ significantly dur-
ing the time period when BBR decreased the phosphorylation state of liver p46 in a time-dependent manner. 
In the dose-response study, treatment of H4IIE cells with BBR at a dose of 10 μM, 25 μM, or 50 μM for 24 hr 
decreased the phosphorylation state of p46 under basal conditions (Fig. 4B). Under palmitate-stimulated con-
ditions, treatment of H4IIE cells with BBR was also able to decrease the phosphorylation state of JNK1 at a 
concentration of 50 μM or 100 μM (Fig. 4B). In particular, the effect of BBR on decreasing the phosphorylation 
state of p46 revealed a dose-dependent manner at the dose range between 10 μM and 50 μM, the conditions 
where BBR treatment did not significantly increase the phosphorylation state of hepatocyte AMPK. Therefore, 
Figure 1. Berberine treatment ameliorates HFD-induced insulin resistance and glucose intolerance. Male 
C57BL/6J mice, at 5–6 weeks of age, were fed a high-fat diet (HFD) for 12 weeks and treated with berberine 
(BBR, 100 mg/kg/d, in phosphate-buffered saline (PBS)) or PBS for the last 4 weeks of HFD feeding. Age- and 
gender-matched C57BL/6J mice were fed a low-fat diet (LFD) for 12 weeks and treated with PBS for the last 
4 weeks of LFD feeding. Data are means ± SE, n = 8–10. (A) Body weight was monitored weekly during the 
feeding/treatment period. (B) Food intake was calculated based on food consumption per day per mouse.  
(C) Insulin tolerance tests (ITT). (D) Glucose tolerance tests (GTT). For C and D, mice were fasted for 4 hr  
and received an intraperitoneal injection of insulin (1 U/kg body weight) (C) or glucose (2 g/kg body weight)  
(D). *P < 0.05 HFD-BBR vs. HFD-PBS for the same time point (C,D).
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these results suggest that the anti-inflammatory effect of BBR in H4IIE cells does not involve increased AMPK 
phosphorylation.
Next, we used primary mouse hepatocytes to confirm the time- and dose-dependent anti-inflammatory effect 
of BBR. Consistent with the results from H4IIE cells, the phosphorylation state of p46 was decreased significantly 
in primary mouse hepatocytes upon BBR treatment for 1 hr, and, to a much larger extent, upon BBR treatment 
for 4 hr under both basal and palmitate-stimulated conditions (Fig. 5A). Unlike in H4IIE cells, BBR treatment 
markedly increased the phosphorylation state of AMPK in primary mouse hepatocytes. However, BBR stimula-
tion of AMPK phosphorylation was not in a time-dependent manner, which was different from BBR suppression 
of p46 phosphorylation. In the dose-response study, treatment of primary mouse hepatocytes with BBR for 4 hr 
at a dose of 5 μM, 10 μM, or 25 μM effectively decreased the phosphorylation state of p46 in a dose-dependent 
manner under basal and/or palmitate-stimulated conditions. Upon treatment with BBR at various doses, AMPK 
phosphorylation was significantly increased, but not in a dose-dependent manner. When the mRNA levels of 
proinflammatory cytokines were measured, treatment with palmitate caused a significant increase in the mRNA 
levels of IL-1β , IL-6, and TNFα compared with control (BSA) (Fig. 5C), which was consistent with the proinflam-
matory effect of palmitate. Upon treatment with BBR, the mRNA levels of IL-6 and TNFα were nearly restored to 
the levels comparable with their respective levels in BSA-treated cells. Taken together, these results confirm that 
the anti-inflammatory effect of BBR appears to be independent of AMPK.
We also examined the direct effects of BBR on fat deposition in primary mouse hepatocytes. In the absence of 
BBR, treatment with palmitate caused a marked increase in fat deposition (Fig. 5D). This stimulatory effect of pal-
mitate was nearly blunted by treatment with BBR. Consistent with changes in hepatocyte fat deposition, palmitate 
induced a marked increase in the mRNA levels of key lipogenic genes such as ACC, FAS, and SREBP1c compared 
with BSA (Fig. 5E). However, the effect of palmitate on inducing lipogenic gene expression was ameliorated upon 
treatment with BBR; although the mRNA levels of CPT1a were also decreased in response to BBR treatment.
Berberine decreases obesity-associated adipose tissue inflammation without altering AMPK 
phosphorylation. Since obesity-associated dysfunctional adipose tissue contributes to a proinflamma-
tory environment that exacerbates the progression of NAFLD6,27, we examined the effect of BBR on adipose 
tissue inflammation. In response to HFD feeding, the phosphorylation state of adipose tissue p46 (in HFD-PBS 
mice) was markedly increased compared with that in LFD-PBS mice, validating adipose tissue inflammation. 
Upon treatment with BBR, the phosphorylation state of adipose tissue p46 was decreased significantly (Fig. 6A). 
However, the phosphorylation state of adipose tissue AMPK in HFD-PBS mice only revealed an insignificant 
Figure 2. Berberine treatment decreases HFD-induced liver inflammatory responses. Mouse experiments 
were performed as descried in Fig. 1. (A,B) Liver inflammatory signaling. Liver extracts were subjected to 
Western blot analyses (A). Ratios of phosphorylated JNK1 to total JNK1 (P-p46/p46) were quantified using 
densitometry and normalized to GAPDH (B). AU, arbitrary unit. (C) Liver mRNA levels of pro-inflammatory 
cytokines were analyzed using quantitative real-time PCR. For bar graphs, data are means ± SE (n = 4–6). 
*P < 0.05, HFD-BBR vs. HFD-PBS; †P < 0.05 and ††P < 0.01 HFD-PBS vs. LFD-PBS.
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decrease compared with that in LFD-PBS mice. Also, treatment with BBR did not significantly increase the phos-
phorylation state of adipose tissue AMPK (Fig. 6A). Consistent with increased adipose tissue inflammatory signa-
ling, percentages of mature macrophages and proinflammatory (M1) macrophages in adipose tissue of HFD-BBR 
mice were significantly higher than their respective percentages in LFD-PBS mice. However, in response to BBR 
treatment, percentages of M1 macrophages in adipose tissue of HFD-fed mice were significantly decreased in rel-
ative to those of HFD-PBS mice while macrophage infiltration and percentages of anti-inflammatory (M2) mac-
rophages were not significantly altered (Fig. 6B). When proinflammatory cytokines were examined, the mRNA 
levels of IL-1β and TNFα in adipose tissue of HFD-PBS mice were significantly higher than their respective levels 
in LFD-PBS mice. Upon treatment with BBR, the mRNA levels of IL-1β and TNFα in adipose tissue of HFD-fed 
mice were significantly decreased in relative to their respective levels in HFD-PBS mice (Fig. 6C). Taken together, 
these results suggest that BBR decreases obesity-associated adipose tissue inflammation independent of AMPK 
phosphorylation.
Discussion
Our previous26 and current studies showed that C57BL/6J mice fed an HFD developed obesity-associated insulin 
resistance, hepatic steatosis, and inflammation in both the liver and adipose tissue. Therefore, HFD-fed mice 
were used as a model of obesity-associated NAFLD to assess the beneficial effects of BBR. Consistent with several 
lines of studies19–21, BBR treatment not only improved HFD-induced hyperglycemia and glucose intolerance, 
but also significantly decreased the severity of liver and adipose tissue inflammation and hepatic steatosis. Using 
in vitro systems involving hepatoma cells and primary mouse hepatocytes, we confirmed that BBR had powerful 
anti-inflammatory effects on hepatocytes in both time-dependent and dose-dependent manners, and that BBR 
had a direct effect on blunting palmitate-induced hepatocyte fat deposition. Of significance, the effects of BBR on 
improving hepatic steatosis and on decreasing liver and adipose tissue inflammation in DIO mice were independ-
ent of AMPK. The same was found for the effect of BBR on suppressing inflammatory responses in hepatocytes. 
Therefore, the present study provides evidence to support that the anti-NAFLD actions of BBR were attributable 
to, in large extent, the anti-inflammatory effect of BBR that occurred in an AMPK-independent manner.
As a bioactive compound from a number of herbals that have long been used to treat inflammatory diseases, 
BBR is well documented to possess powerful anti-inflammatory properties. In support of this, BBR is capable of 
decreasing proinflammatory responses in a wide range of cells including macrophages, hepatocytes, and adipo-
cytes24,28–30. Over the last two decades, the use of BBR has been extended to type 2 diabetes aiming at lowering 
hyperglycemia and hyperlipidemia17–20. More recently, BBR has also been used to treat fatty liver disease19,20. 
However, the extent to which the anti-inflammatory properties of BBR account for its anti-NAFLD actions 
remains to be explored. In the present study, BBR treatment significantly ameliorated HFD-induced inflammation 
Figure 3. Berberine treatment ameliorates fat deposition in the liver and decrease hepatic expression of 
lipogenic genes. Mouse experiments were performed as descried in Fig. 1. (A) Liver weight. (B) Liver sections 
for H&E staining (top panels) and Oil Red O staining (bottom panels). (C) Liver AMPK signaling. Liver extracts 
were subjected to Western blot analyses. Ratios of phosphorylated AMPK to total AMPK (P-AMPK/AMPK) 
and phosphorylated ACC to total ACC (P-ACC/ACC) were quantified using densitometry and normalized 
to GAPDH (bar graphs). AU, arbitrary unit. (D) Liver mRNA levels of genes related to fat metabolism were 
analyzed using quantitative real-time PCR. For all bar graphs, data are means ± SE (n = 4–7). *P < 0.05 and 
**P < 0.01 HFD-BBR vs. HFD-PBS; †P < 0.05 HFD-PBS or HFD-BBR vs. LFD-PBS.
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in both the liver and adipose tissue as indicated by decreases in the proinflammatory signaling through p46 and 
in the mRNA levels of proinflammatory cytokines such as IL-1β , IL-6, and/or TNFα . Furthermore, treatment 
of two types of hepatocytes, hepatoma H4IIE cells and primary mouse hepatocytes, with BBR brought about 
similar effects on decreasing the proinflammatory signaling through p46 and/or the mRNA levels of IL-1β , IL-6, 
and TNFα . In addition, in both types of hepatocytes, the anti-inflammatory effect of BBR appeared to be both 
time-dependent and dose-dependent. Of importance, BBR treatment also brought about beneficial effects on 
hepatic steatosis in HFD-fed mice and on palmitate-induced fat deposition in hepatocytes. These effects were 
correlated well with the anti-inflammatory effects of BBR, but not AMPK phosphorylation state (see below). 
Considering the role of inflammation31–36, in particular the role for JNK131,34, in promoting hepatic steatosis, the 
results from both in vivo and in vitro experiments of the present study indicate that BBR suppression of hepat-
ocyte inflammatory responses critically contributes to a decrease in hepatocyte fat deposition, thereby hepatic 
steatosis.
While displaying anti-inflammatory effects, BBR treatment also increases liver AMPK phosphorylation (activa-
tion)21,37. When activated, AMPK is capable of suppressing lipogenesis through phosphorylating and inactivating 
the lipogenic enzyme ACC. In addition, a decrease in the production of malonyl-CoA due to AMPK inhibition 
of ACC brings about an increase in fatty acid oxidation via releasing the inhibitory effect of malonyl-CoA on 
CPT1a38. These combined effects of AMPK activation are considered to largely account for BBR actions on reduc-
ing hepatic steatosis as described by previous studies21,23. In the present study, however, AMPK appeared to not 
be involved in BBR actions as supported by two lines of evidence. First, treatment of DIO mice with BBR did not 
significantly alter the phosphorylation state of AMPK in both the liver and adipose tissue. Second, when the direct 
effects of BBR were examined, BBR did not significantly increase the phosphorylation state of AMPK at the time 
points where BBR decreased the phosphorylation state of p46 in a time-dependent manner. In addition, BBR did 
Figure 4. Berberine treatment decreases JNK1 phosphorylation while showing limited effects on AMPK 
phosphorylation in H4IIE cells. (A) Time-course study. H4IIE cells were pre-treated with palmitate (250 μM, 
conjugated with bovine serum albumin (BSA)) or BSA for 2 hr and then supplemented with berberine (BBR, 
25 μM in PBS) or PBS for an additional 10 min, 1 hr, 4 hr, 8 hr, and/or 24 hr. (B) Dose-response study. H4IIE 
cells were pre-treated with palmitate (250 μM) or BSA for 2 hr and then supplemented with BBR or PBS for an 
additional 24 hr. For (A,B), cell extracts were subjected to Western blot analyses. Left panels, representative 
blots. For all bar graphs, ratios of phosphorylated AMPK to total AMPK (P-AMPK/AMPK) and phosphorylated 
JNK1 to total JNK1 (P-p46/p46) were quantified using densitometry and normalized to GAPDH. AU, arbitrary 
unit. Data are means ± SE (n = 4). *P < 0.05 and **P < 0.01 vs. BBR 0 (in B); Labeled means without a common 
letter under the same condition (BSA or Pal), P < 0.05 (in A,B).
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not increase the phosphorylation state of AMPK at the dose range where BBR decreased the phosphorylation state 
of p46 in a dose-dependent manner in H4IIE cells. Thus, BBR appeared to act through AMPK-independent mech-
anisms to decrease hepatic steatosis in DIO mice and to suppress palmitate-stimulated fat deposition in H4IIE cells. 
To be noted, metformin has been previously shown to suppress palmitate-stimulated fat deposition in H4IIE cells, 
and this effect of metformin was attributable to, at least in part, increased AMPK phosphorylation26. Upon care-
fully comparing the effects between BBR and metformin in H4IIE cells, we argue in favor that, unlike metformin 
actions, BBR suppression of hepatocyte fat deposition was associated with the anti-inflammatory effect of BBR, but 
not the AMPK phosphorylation state. This also explained well that the effects of BBR on decreasing HFD-induced 
hepatic steatosis were associated with a decrease in liver inflammation, but not AMPK phosphorylation.
Our findings on BBR regulation of AMPK phosphorylation were different from those reported by Brusq 
et al.37 and Kim et al.21. While further studies are needed to explore exactly why the discrepancies exist, it is pos-
sible that BBR regulation of AMPK phosphorylation varies depending on mouse models used and the methods 
of how BBR was delivered. In the study by Brusq et al. Syrian golden hamsters were fed an HFD for 2 weeks and 
Figure 5. Berberine treatment suppresses the proinflammatory responses and ameliorates fat deposition 
in mouse primary hepatocytes while differentially altering AMPK. (A) Time-course study. Primary mouse 
hepatocytes were pre-treated with palmitate (250 μM, conjugated with bovine serum albumin (BSA)) or BSA 
for 2 hr and then supplemented with berberine (BBR, 25 μM in PBS) or PBS for an additional 1 hr and/or 4 hr. 
(B) Dose-response study. Primary mouse hepatocytes were pre-treated with palmitate (250 μM) or BSA for 
2 hr and then supplemented with BBR at a dose of 5, 10, or 25 μM or PBS for an additional 4 hr. For (A,B), top 
panels, representative blots. Bar graphs, ratios of phosphorylated AMPK to total AMPK (P-AMPK/AMPK) 
and phosphorylated JNK1 to total JNK1 (P-p46/p46) were quantified using densitometry and normalized to 
GAPDH. AU, arbitrary unit. Data are means ± SE (n = 4). **P < 0.01 vs. BBR 0 (in A,B); Labeled means without 
a common letter under the same condition (BSA or Pal), P < 0.05. (C) Hepatocyte proinflammatory cytokine 
expression. (D) Hepatocyte fat deposition. (E) Hepatocyte mRNA levels of genes related to fat metabolism. For 
(C–E), primary mouse hepatocytes were as described in A with or without palmitate for 2 hr in the presence or 
absence of BBR for an additional 4 hr. For (C,E), the mRNA levels of pro-inflammatory cytokines and metabolic 
genes were analyzed using quantitative real-time PCR. For bar graphs in (C,E), data are means ± SE (n = 4–6). 
*P < 0.05 and **P < 0.01 Pal+ BBR vs. Pal; †P < 0.05 and ††P < 0.01 Pal vs. BSA.
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used as a model of NAFLD whereas we used DIO mice. Much evidence has documented that hamsters are mark-
edly different from mice. In the study by Kim et al. although obese mice were used as a model of NAFLD, BBR 
was delivered via intraperitoneal (IP) injections, but not oral gavages. Moreover, IP BBR injections brought about 
a decrease in body weight and an increase in whole body energy expenditure, which both may increase AMPK 
phosphorylation. In other words, the increase in liver AMPK phosphorylation observed by Kim et al. may be the 
secondary effects of BBR. Also, the study by Kim et al. did not validate the direct effect of BBR on altering AMPK 
phosphorylation in cultured hepatocytes. In contrast, we examined the direct effect of BBR in cultured hepato-
cytes, i.e., H4IIE cells and primary mouse hepatocytes, and our results suggest that the anti-inflammatory effects 
of BBR appear to be independent of AMPK phosphorylation. These findings were consistent with those observed 
in both HepG2 hepatocytes and C2C12 myotubes39, where BBR treatment promotes glucose consumption inde-
pendent of AMPK. Given this, it is conceivable that activating AMPK is not a primary mechanism by which BBR 
exerts anti-NAFLD effects. However, our interpretation does not necessarily rule out a contribution of AMPK 
activation to, at a certain extent, the beneficial effects of BBR.
The role for obesity-associated dysfunctional adipose tissue in the development of NAFLD also has been well 
established. On the one hand, adipose tissue delivers excessive free fatty acids to the liver, thereby facilitating 
hepatic steatosis. On the other hand, adipose tissue secretes proinflammatory mediators that trigger or exacer-
bate liver inflammation as a key element of NAFLD. In the present study, treatment of DIO mice with BBR did 
not alter visceral fat mass and adiposity. In contrast, BBR treatment ameliorated adipose tissue inflammatory 
responses as indicated by significant decreases in the proinflammatory signaling through p46, percentages of M1 
macrophages, and the mRNA levels of proinflammatory cytokines. Clearly, these results suggest an involvement 
of improved adipose tissue inflammation in the beneficial effects of BBR on aspects of NAFLD. However, the 
Figure 6. Berberine treatment decreases adipose tissue inflammatory responses without altering AMPK 
phosphorylation. Mice were treated as described in Fig. 1. After the feeding/treatment period, mice were fasted 
for 4 hr prior to collection of tissue samples. (A) Adipose tissue AMPK signaling and inflammatory signaling 
were examined using Western blot analyses. Ratios of phosphorylated AMPK to total AMPK (P-AMPK/AMPK) 
and phosphorylated JNK1 to total JNK1 (P-p46/p46) were quantified using densitometry and normalized to 
GAPDH (bar graphs). (B) Adipose tissue macrophage infiltration and polarization. Percentages of mature 
macrophages (F4/80+ CD11b+ cells) in adipose tissue stromal cells, as well as percentages of proinflammatory 
(M1, F4/80+ CD11b+ CD11c+ CD206− cells) and anti-inflammatory (M2, F4/80+ CD11b+ CD11c− CD206+ 
cells) among mature adipose tissue macrophages were calculated using FACS analyses. (C) The mRNA levels 
of adipose genes were quantified using real-time PCR. For bar graphs, data are means ± SE. n = 6–8). *P < 0.05 
and **P < 0.01 HFD-BBR vs. HFD-PBS; †P < 0.05 and ††P < 0.01 HFD-PBS or HFD-BBR vs. LFD-PBS.
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proportional contribution of improved inflammation in the liver and adipose tissue to the overall improvement 
of NAFLD in DIO mice is not known, and may warrant future investigations.
In summary, the present study provided evidence to support the potential therapeutic effects of BBR on reduc-
ing liver inflammation and steatosis while improving systemic insulin sensitivity and glucose homeostasis. The 
mechanisms underlying the beneficial effects of BBR could result largely from the anti-inflammatory effect of 
BBR. In addition, BBR appears to have a limited role in increasing AMPK phosphorylation state in the context 
of NAFLD. Taken together, our results validate the potential of using BBR for treatment and/or prevention of 
obesity-associated NAFLD.
Materials and Methods
Animal experiments. C57BL/6J mice were obtained from the Jackson Laboratory and maintained on a 
12:12-h light-dark cycle (lights on at 06:00). At 5–6 weeks of age, male mice were fed a high-fat diet (HFD, 60% 
fat calories, 20% protein calories, and 20% carbohydrate calories) for 12 weeks and treated with BBR (100 mg/
kg body weight/d, suspension in PBS) or PBS via oral gavages for the last 4 weeks. The dose of BBR was chosen 
based on our pilot study and published literature37. As additional controls, gender- and age-matched C57BL/6J 
mice were fed a low-fat diet (LFD, 10% fat calories, 20% protein calories, and 70% carbohydrate calories) for 12 
weeks and treated with PBS for the last 4 weeks. Both diets are products of Research Diets, Inc (New Brunswick, 
NJ) and contain the same amount of casein, L-cysteine, cellulose, sucrose, soybean oil, and minerals. However, 
the HFD contains much more lard but none corn starch compared with the LFD. During the 12-week feeding/
treatment period, body weight and food intake of the mice were recorded weekly. After the feeding/treatment 
period, mice were fasted for 4 hr before sacrifice for collection of blood and tissue samples25,40,41. Liver weight 
was recorded. Also, epididymal, mesenteric, and perinephric fat depots were dissected and weighed as visceral fat 
content25. After weighing, part of epididymal fat was subjected to isolation of stromal vascular cells as described 
below. Additional liver and adipose tissue samples were either fixed and embedded for histological analyses (H&E 
staining) or frozen in liquid nitrogen and stored at − 80 °C for further analyses25. Some mice were fasted similarly 
and used for insulin and glucose tolerance tests as described below. All animals received human care and all study 
protocols were approved by the Institutional Animal Care and Use Committee of Texas A&M University. In addi-
tion, all experiments were performed in accordance with relevant guidelines and regulations.
Insulin and glucose tolerance tests. Mice were fasted for 4 hr and received an intraperitoneal injection of 
insulin (1 U/kg body weight) or D-glucose (2 g/kg body weight). For insulin tolerance tests, blood samples (5 μl) 
were collected from the tail vein before and at 15, 30, 45, and 60 min after the bolus insulin injection. Similarly, for 
glucose tolerance tests, blood samples were collected from the tail vein before and at 30, 60, 90 and 120 min after 
the glucose bolus injection42,43. The levels of plasma glucose were measured using an enzymatic assay kit (Sigma, 
St. Louis, MO).
Isolation of stromal vascular cells from adipose tissue. Adipose tissue stromal vascular cells (SVC) 
were isolated using the collagenase digestion method as previously described42,44. After digestion and centrifuga-
tion, the pelleted cells were collected as SVC and subjected to FACS analyses.
Flow cytometry analysis. Adipose tissue SVC were stained with fluorescence-tagged antibodies: 
anti-F4/80, anti-CD11b for macrophages, and anti-CD11c and anti-CD206 for macrophage inflammatory status 
as previously described45, and subjected to FACS analyses using BD Accuri C6 flow cytometer (BD Biosciences, 
San Jose, California, USA).
H&E and Oil-Red-O staining. The paraffin-embedded livers were cut into sections of 5 μm thickness and 
stained with hematoxylin and eosin (H&E) while frozen liver sections were stained with Oil-Red-O as previously 
described46.
Cell culture and treatment. H4IIE cells (rat hepatoma cells) were maintained in high glucose Dulbecco’s 
modified eagle medium (DMEM) supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 
100 μg/l streptomycin as previously described15,16. At 80% confluence, H4IIE cells were subjected to the following 
studies. In a time-course study, H4IIE cells were pre-treated with palmitate (250 μM, conjugated with BSA) or 
BSA for 2 hr and then supplemented with BBR (25 μM in PBS) or PBS for an additional 10 min, 1 hr, 4 hr, 8 hr, 
and/or 24 hr. For a dose-response study, H4IIE cells were pre-treated with palmitate (250 μM) or BSA for 2 hr 
and then supplemented with BBR or PBS for an additional 24 hr. In addition, primary mouse hepatocytes were 
isolated as previously described15,16 and subjected to time-course and dose-response studies in the same ways for 
H4IIE cells. Briefly, after attachment, primary mouse hepatocytes were pre-treated with palmitate (250 μM) for 
2 hr and then supplemented with BBR (25 μM) or PBS for an additional 1 hr and/or 4 hr. In a dose-response study, 
primary mouse hepatocytes were pre-treated with palmitate (250 μM) or BSA for 2 hr and then supplemented 
with BBR at a dose of 5, 10, or 25 μM or PBS for an additional 4 hr. Additional primary hepatocytes were treated 
with or without palmitate for 2 hr in the presence or absence of BBR for an additional 4 hr to measure the mRNA 
levels of pro-inflammatory cytokines and metabolic genes. To examine lipid accumulation, the treated hepato-
cytes were stained with Oil-Red-O for the last 1 hr.
Western blots. Lysates were prepared from frozen tissue samples and cultured cells using the lysis buffer 
containing 50 mm HEPES (pH 7.4), 1% Triton X-100, 50 mm sodium pyrophosphate, 0.1 m sodium fluoride, 
10 mm EDTA, 10 mm sodium orthovanadate, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 2 mm benzamidine, and 
2 mm phenylmethylsulfonyl fluoride. After protein electrophoresis and transfer, immunoblots were performed 
using rabbit anti-serum as primary antibody at a 1:1,000 dilution. The blot was followed by a 1:10,000 dilution 
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of goat anti-rabbit horseradish peroxidase-conjugated secondary antibody kit (Immobilon™ Western; EMD 
Millipore, Billerica, MA, USA) as previously described25. GAPDH was used as a loading control. The maximum 
intensity of each band was quantified using ImageJ software. Ratios of P-AMPK/AMPK, P-ACC/ACC, and P-p46/
p46 were normalized to GAPDH and adjusted relative to the average of PBS-treated control, which was arbitrarily 
set as 1 (AU).
RNA isolation, reverse transcription, and real-time PCR. The total RNA was isolated from frozen 
tissue samples and cultured/isolated cells. Reverse transcription was performed using the GoScript™ Reverse 
Transcription System (Promega) and real-time PCR analysis was performed using SYBR Green (LightCycler® 
480 system; Roche)16,41,47. The mRNA levels were analyzed for ACC1, FAS, CPT1a, SREBP1c, IL-1β , IL-6, TNFα , 
adiponectin, and/or resistin in tissue and/or cell samples. A total of 0.1 μg RNA was used for the determination. 
Results were normalized to 18s ribosomal RNA as plotted as relative expression to the average of PBS-treated 
control, which was set as 1.
Statistical Methods. Numeric data are presented as means ± SE (standard error). Two-tailed Student’s t 
tests and/or two-tailed ANOVA were used for statistical analyses. Differences were considered significant at the 
P < 0.05.
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